Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.
Doody RS, et al.
N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.
N Engl J Med. 2014.
PMID: 24450890
Free article.
Clinical Trial.